Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 5/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899949 | 0.90 | ICMT (0.42) | ICMTCYSLTR2CYSLTR1F2PRSS1 | |
| SCHEMBL4657990 | 0.86 | PLA2G2A (0.49) | ICMTCYSLTR2CYSLTR1F2PRSS1 | |
| SCHEMBL4658881 | 0.85 | HDAC1 (0.42) | ICMTF2PRSS1PPARGPLA2G2A | |
| SCHEMBL5899841 | 0.84 | HDAC1 (0.43) | ICMTF2PRSS1PLA2G2ABRD4 | |
| SCHEMBL4626809 | 0.82 | ICMT (0.47) | ICMTCYSLTR2CYSLTR1F2PRSS1 | |
| SCHEMBL4658856 | 0.81 | PLA2G2A (0.43) | CYSLTR2CYSLTR1F2PRSS1PPARG | |
| SCHEMBL5899946 | 0.79 | PLA2G2A (0.47) | ICMTF2PRSS1PPARGPLA2G2A | |
| SCHEMBL5899891 | 0.79 | PLA2G2A (0.52) | ICMTCYSLTR2CYSLTR1F2PRSS1 | |
| SCHEMBL4656156 | 0.79 | PLA2G2A (0.51) | ICMTF2PRSS1PLA2G2ATP53 | |
| SCHEMBL5900071 | 0.78 | MTNR1A (0.47) | F2PRSS1PPARGPLA2G2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | claimed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | claimed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | TFPI, TFPI2, F2 | ICMT 2334/4885CYSLTR2 1572/4885CYSLTR1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.